Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
|Videos|February 23, 2021
Living Through an Episode
Author(s)Susan J. Noonan, MD, MPH
When dealing with a serious mental illness, speaking out and sharing common experiences can help healing.
Advertisement
Susan J. Noonan, MD, MPH, talks about how finding a community and sharing experiences can help people going through an episode.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
4
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
5